Inhibrx (INBX) Director Jon Faiz Kayyem Buys 5,000 Shares

What Happened
Jon Faiz Kayyem, a director of Inhibrx Biosciences, acquired 5,000 shares of INBX on September 8, 2026 in an open-market purchase (code P). The reported weighted-average purchase price was $113.52 per share, for a total transaction value of approximately $567,580. This was a purchase (an acquisition), which insiders buying shares can be viewed as a potentially bullish action, though motivations are not disclosed.

Key Details

• Transaction date: September 8, 2026. Report filed the same day (no late filing indicated).
• Purchase details: 5,000 shares at a reported weighted-average price of $113.52; underlying trades ranged from $113.30 to $113.55 (footnote F1).
• Shares owned after transaction: not specified in the provided filing.
• Ownership/holding structure: the filing shows these securities are held in various trusts and custodial accounts associated with the reporting person and family (footnotes F2–F6). The reporting person serves as trustee for certain trusts and disclaims beneficial ownership of some accounts except for any indirect pecuniary interest.
• Footnote provision: the reporting person will provide, upon request, full details of the number of shares and exact prices for the multiple transactions that make up the weighted-average price (F1).

Context

• Code P = Purchase (open market/private). Purchases by directors are often of interest to retail investors because they represent insiders putting personal capital into the company, but they do not by themselves prove future performance.
• Several lots were aggregated into the single reported entry; detailed trade-level prices/quantities are available from the filer upon request per the footnote.